Table 5

Correlation between NY-ESO-1 expression (mRNA and/or IHC) and clinicopathological features in EOC

Pathological and clinical featuresNY-ESO-1 positiveNY-ESO-1 negative
All tumors (n = 190)82 (43.2%)108 (56.8%)
Age, median (range), years62 (22–84)59 (26–89)
Tumor grade (n)
 G129
 G255
 G37594
FIGO stage (n)
 Ia14
 Ib1
 Ic13
 IIb13
 IIC7
 IIIa
 IIIb4
 IIIc7178
 IV78
Histology (n)
 Papillary serous6578
 Clear cell26
 Endometroid17
 Mucinous22
 Undifferentiated24
 Others (transitional, mixed, carcinosarcoma)76
Response, n (%)
 Complete response36 (44%)61 (51%)
 Partial response42 (51%)39 (36%)
Total Recurrences/persistent disease,a n (%)67 (82%)71 (66%)
Dead of disease, n (%)35 (43%)42 (39%)
Alive with disease, n (%)31 (38%)28 (36%)
Alive with no evidence of disease, n (%)16 (20%)37 (34%)
  • a Median disease-free survival (excluding patients with persistent disease) for patients with NY-ESO-1-negative and -positive tumors: 32 (18–46) and 32 (17–47) months, respectively (P = 0.74).